Navigation Links
Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
Date:9/22/2010

HAYWARD, Calif., Sept. 22 /PRNewswire/ -- Intarcia Therapeutics, Inc. presented today final results of a 24-week phase 2 clinical study of ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden.

(Logo: http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

Results of the phase 2 study demonstrated substantial reductions in HbA1c and body weight during the 24 weeks of treatment with ITCA 650 at all doses.  A starting ITCA 650 dose of 20 mcg/day for weeks 1 through 12 provided effective glycemic control with the best tolerability profile.  A transition to ITCA 650 at 60 mcg/day for weeks 13 through 24 was well tolerated and provided substantial incremental reductions in both HbA1c and body weight at week 24. An ITCA 650 treatment regimen involving a 20 mcg/day starting dose with a transition to 60 mcg/day after week 12 has been selected for a phase 3 clinical trial, anticipated to begin enrollment in early 2011.

"We are very encouraged by the results observed in this study and the high level of enthusiasm expressed by patients and investigators," said Kurt Graves, executive chairman of the board for Intarcia. "ITCA 650 is a novel therapeutic approach for type 2 diabetes that holds new promise for many patients and physicians who want highly effective glucose reductions and weight loss without the tradeoff associated with having to start potentially lifelong and frequent self-injections." Graves added, "ITCA 650 also holds the promise to ensure patient compliance and long-term control given the breakthrough nature of its continuous delivery with just one or two placements
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Pa. , July 10, 2014 ... Moberg Research,s (Moberg) medical device manufacturing facility. Rep. ... Moberg,s advanced neurological monitors facilitate cutting-edge research in ... Rep. Kennedy and mental health advocate, Garen ... organization dedicated to fostering fundamental changes that will ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
(Date:7/10/2014)... July 10, 2014 CVS Caremark Corporation (NYSE: ... has approved a quarterly dividend of $0.275 (27.5 cents) per ... on August 1, 2014, to holders of record on July ... CVS Caremark is dedicated to helping people on their path ... the United States . Through the company,s ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Among High-Risk Infants Versus,Current Standard of Care ... Related Lower Respiratory Infections -, TORONTO, May ... positive results from a large prospective trial,conducted ... The,trial compared motavizumab, the investigational monoclonal antibody,(MAb) ...
... Presentation for Pristiq Occurs at the 55th ... Obstetricians and,Gynecologists, COLLEGEVILLE, Pa., May 09, 2007 ... , presented results from the,first Phase 3 ... moderate-to-severe vasomotor symptoms (hot flashes,and night sweats) ...
Cached Medicine Technology:MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 2MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 3MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 4MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 5MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 6MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 7Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 2Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 3Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 4Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 5Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 6
(Date:7/12/2014)... Using and carrying around a catheter ... from Ashland, Va., decided that there needed to be ... to conceive of our design," he said. , They ... which provides an inconspicuous way to use and carry ... as promotes comfort and peace of mind. Producible in ...
(Date:7/12/2014)... July 12, 2014 “Critical Care ... New and Late-Stage Four-Factor PCCs and Recombinant Products ... the critical care market in the US, UK, ... report provides an estimation of market size for ... covers critical care indications that are being treated ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 A recent article ... provides a trio of suggestions for those seeking cosmetic ... days are rapidly approaching and the heat begins to enliven ... to their summer clothing, realizing that they didn’t work out ... , This can cause a sudden surge of people eager ...
(Date:7/12/2014)... Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
(Date:7/11/2014)... July 11, 2014 The American Association ... 55 poison centers are commending Senator Bill Nelson (D-FL) ... Act of 2014 on July 10, 2014. Along with ... Products Safety Commission (CPSC) to enact rules requiring safer, ... , Senate co-sponsors of the bill include: ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3
... Blue Plan Experienced a 15 Percent Increase ... a New Report from HealthLeaders-InterStudy, NASHVILLE, ... of managed care market intelligence, reports that ... medication use,through pharmacy programs and public education ...
... Health,Care Systems, Inc. (HCS), a leading provider ... medication reconciliation solutions, has entered,into an agreement with ... not-for-profit hospitals in the nation with 881 licensed,acute ... facility for The,University of Alabama at Birmingham,s Family ...
... treatment could help 3.3 million U.S. sufferers, ... Medical, Inc. today,announced that 98.4 percent of ... called Barrett,s esophagus were free of the ... the HALO ablation,system. The results were published ...
... release of milk in humans, animals , , FRIDAY, July 18 ... speaking? , Researchers have discovered that babies nursing at ... to release of oxytocin, known as the "trust" hormone in ... to be involved in trust and love in both humans ...
... restored brain,s ability to make new cells , , FRIDAY, July ... day may lead to health issues, including depression, a new ... a causal link between abstinence from alcohol drinking and depression," ... and pharmacology in the University of North Carolina School of ...
... in French . , Winnipeg (July ... Canadian Institutes of Health Research (CIHR) was announced today ... Secretary for Health, on behalf of Tony Clement, Minister ... investigating how to improve the application of mental health ...
Cached Medicine News:Health News:New York's Excellus BlueCross BlueShield to Continue Generic Medication Promotion to Help Control Costs 2Health News:Huntsville Hospital Signs With Health Care Systems, Inc. for Automated Medication Reconciliation Services 2Health News:Precancerous Esophagus Disease Eliminated in 98.4% of Patients Treated With HALO Ablation System 2Health News:Precancerous Esophagus Disease Eliminated in 98.4% of Patients Treated With HALO Ablation System 3Health News:Suckling Infant Triggers 'Trust' Hormone in Moms 2Health News:Research Finds Causal Link Between Ending Drinking, Depression 2Health News:CIHR announces $4.4 million to improve mental health of Canadians 2
This a new dedicated VICTOR2 model for fluorescence, fluorescence polarization and luminescence measurement with stacker and robotic loading....
This a new dedicated VICTOR2 model for fluorescence and luminescence detection with stacker and robotic loading....
This is the modular manually operated VICTOR2 multilabel counter, with the addition of a xenon flash lamp for time-resolved fluorescence counting. Along with this option comes flash absorbance and du...
... multimode readers offering 96-channel parallel detection of ... and 1,536-well microtiter plates. Compact workstations ... for the transport of microtiter plates with ... day. The need for mechanical switching required ...
Medicine Products: